**Case Report**

**Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma**

Akihiro Yoshimura,1 Kazuaki Yamanaka,1,† Rei Tadokoro,2 Teppei Wakita,1 Shota Fukae,1 Takahiro Yoshida,1 Masahiro Sekiguchi2 and Hidefumi Kishikawa1

Departments of 1Urology and 2Rheumatology, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya City, Hyogo, Japan

**Abbreviations & Acronyms**

CT = computed tomography  
I-O = immuno-oncology  
irAE = immune-related adverse event  
RS3PE = remitting seronegative symmetrical synovitis with pitting edema

**Correspondence:** Kazuaki Yamanaka M.D., Ph.D., Department of Urology, Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokutanji-cho, Nishinomiya City, Hyogo 662-0918, Japan. Email: yaki578410@gmail.com

**How to cite this article:** Yoshimura A, Yamanaka K, Tadokoro R, et al. Remitting seronegative symmetrical synovitis with pitting edema syndrome induced by pembrolizumab in patient with urothelial carcinoma. *IJU Case Rep*. 2022; 5: 219–222.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Received 16 November 2021; accepted 7 February 2022. Online publication 3 May 2022

**Introduction:** Recent introduction of immuno-oncology drugs such as pembrolizumab has resulted in improved outcomes for urothelial carcinoma patients. However, immune-related adverse events generally show great variance and are often difficult to diagnose and control.

**Case presentation:** An 84-year-old Japanese male with urothelial carcinoma metastasis to the lungs after a laparoscopic left radical nephroureterectomy procedure was treated with pembrolizumab, an immuno-oncology drug, as second-line therapy. At week 6, inflammatory arthralgia involving the hands and shoulder joints, and edema of the hands were presented. The diagnosis was remitting seronegative symmetrical synovitis with pitting edema syndrome. Pembrolizumab was discontinued, and oral corticosteroid therapy was started. Two months later, pembrolizumab treatment was resumed because of a significant improvement in patient condition.

**Conclusion:** Although rare, immune-related adverse events are occasionally encountered during the use of immuno-oncology drugs; thus, early diagnosis and appropriate treatment are important.

**Key words:** connective tissue disease, drug related side effects and adverse reactions, immune checkpoint inhibitors, pembrolizumab, transitional cell carcinoma.

**Keynote message**

It is important to note that pembrolizumab, a drug prescribed for the treatment of urothelial carcinoma, activates the immune system and can cause RS3PE syndrome, a relatively rare collagen disease, as an immune-related adverse event.

**Introduction**

Recent introduction of I-O drugs such as pembrolizumab have resulted in improved outcomes for urothelial carcinoma patients. However, as compared to cases undergoing conventional chemotherapy, irAEs have greater variance and are often more difficult to diagnose and control. For example, while arthritis is a common symptom of rheumatic irAE, there are few reports of occurrence of RS3PE syndrome as an irAE. This syndrome, first reported in 1985, is an atypical presentation of arthritis, characterized by sudden onset symmetric distal synovitis and pitting edema of the hands and occurs more often in older individuals with a male predominance. Inflammatory markers such as CRP are usually elevated, while the rheumatoid factor is negative, and this syndrome is usually highly sensitive to low-dose corticosteroid therapy. We report a case of RS3PE syndrome in a metastatic urothelial carcinoma patient that was presented during pembrolizumab therapy.

**Case presentation**

An 84-year-old Japanese male was presented with left abdominal pain, and CT scan findings revealed a tumor of the left ureter and hydronephrosis. The patient underwent a
lupus erythematosus or other irAEs. The present strategy for this case is further reduction of prednisolone medication and eventual termination in the absence of a flare-up of symptoms.

Discussion

I-O drugs exert antitumor effects by activating immune response against tumor cells, though it has also been suggested that they cause irAEs due to excessive autoimmune response. RS3PE syndrome is an uncommon irAE, with only eight known cases reported at the time of writing (Table 1). Those show that patients with RS3PE syndrome respond markedly to steroid therapy and most go into remission; thus, progressive reduction or discontinuation of the steroid can be expected. As for RS3PE syndrome that develops during I-O drug administration, the majority of reports suggest discontinuation of any such drug as a treatment strategy. However, some have indicated that the clinical condition of patients affected by this syndrome could be controlled with an I-O drug; thus, the need for discontinuation remains inconclusive. Furthermore, reports of flare-ups of irAEs after restarting I-O drug treatment and during steroid reduction have been presented; thus, careful monitoring of symptoms is required even after resumption.3,4

RS3PE syndrome has been regarded as a paraneoplastic syndrome in 24.7% of all reported cases.5 When this syndrome develops in patients with urothelial carcinoma being treated with an immune checkpoint inhibitor, it is necessary to distinguish between paraneoplastic syndrome and an irAE. However, it is difficult to differentiate between these etiologies as there are no apparent differences in clinical symptoms, laboratory findings, or image examination findings. Poor response to corticosteroid treatment has been observed in paraneoplastic RS3PE syndrome patients.6 Yamamoto et al. also reported RS3PE syndrome that developed after 17 courses of pembrolizumab therapy for urothelial carcinoma, in which improvement was noted with low-dose corticosteroid treatment and continuation of pembrolizumab.7 However, findings presented in that study did not elucidate whether irAE or paraneoplastic syndrome was the cause. Symptoms in the present case were noted early following the start of pembrolizumab administration, with recovery demonstrated after temporarily stopping the I-O drug and treatment with low-dose prednisolone. Cancer progression was stable; thus, we considered that RS3PE syndrome was caused by an irAE. Accumulation of case reports is necessary to elucidate the pathogenesis of RS3PE syndrome in association with irAE and paraneoplastic disease in order to select appropriate treatment.

Some reports have found that low-dose steroid therapy does not alter the anti-tumor effects of I-O drugs, while others have noted that steroids reduced the effect of I-O drugs, leading to a poor cancer prognosis.8,9 The risks and benefits of using steroid treatment in patients receiving immune checkpoint inhibitor therapy should be carefully considered.

Conclusion

We report here a case of RS3PE syndrome that developed during pembrolizumab therapy for metastatic urothelial carcinoma. The symptoms were significantly improved by temporary discontinuation of the drug and corticosteroid therapy.
| Reference (no.) | Age (years) | Gender | Disease | I-O drug | Onset of symptoms after initial I-O drug administration | Initial treatment for RS3PE | Discontinuation of I-O drug | Therapeutic course | Readministration of I-O drug | Symptom relapse after readministration |
|----------------|------------|--------|---------|----------|--------------------------------------------------------|-------------------------------|-----------------------------|-----------------|-----------------------------|---------------------------------|
| Kim et al.10    | 59         | Male   | Prostate cancer | Ipilimumab + abiraterone acetate | 3 courses (every 3 weeks) | Weekly methotrexate (15 mg) with daily folic acid (1 mg) | Yes | Remission | No | Yes |
| Wada et al.11   | 70         | Male   | Malignant melanoma | Nivolumab | 7 courses (every 2 weeks) | Prednisolone (10 mg/day) | No | Remission | Yes | Yes (symptoms relapsed after each administration of nivolumab and could be controlled by small amount of steroid) |
| Hansmaennel et al.12 | 79 | Male | Malignant melanoma | Pembrolizumab | 11 months | Prednisone (60 mg/day) | No | Remission | Yes | Unknown |
| Gauci et al.13  | 80         | Male   | Malignant melanoma | Nivolumab | 2 courses (every 2 weeks) | Corticosteroid (0.5 mg/kg/day) | Yes | Remission | Yes | Yes (spontaneous remission within 2 weeks without increase in corticosteroid dose) |
| Ngo et al.14    | 70         | Male   | Malignant melanoma | Nivolumab | 4 months | Prednisone (0.5 mg/kg/day) | No | Remission and relapse after tapering corticosteroid | Yes | No (prednisone maintained at 7.5 mg/day) |
| Filetti et al.15 | 57 | Female | Lung cancer | Nivolumab | 18 months (28 nivolumab administrations) | Prednisone (1 mg/kg/day) | Yes | Remission | Yes | No |
| Amiri-Adle et al.16 | 70 | Male | Malignant melanoma | Nivolumab + ipilimumab | 6 weeks | Prednisone (1000 mg/day) | Yes | Remission and relapse after tapering corticosteroid | No | Yes |
| Redman et al.17  | 70         | Male   | Prostate cancer | Durvalumab | 1 week | Prednisone (15 mg/day) | Yes | Remission | Yes | Yes (symptoms relapsed after steroid withdrawal) |
| Present patient | 84         | Male   | Urothelial carcinoma | Pembrolizumab | 2 courses (every 3 weeks) | Prednisolone (30 mg/day) | Yes | Remission | Yes | No |
Author Contributions
Akihiro Yoshimura: Data curation; Investigation; Visualization; Writing – original draft. Kazuaki Yamanaka: Conceptualization; Project administration; Writing – review & editing. Rei Tadokoro: Writing – review & editing. Teppei Wakita: Writing – review & editing. Shota Fukae: Writing – review & editing. Takahiro Yoshida: Writing – review & editing. Masahiro Sekiguchi: Writing – review & editing. Hidefumi Kishikawa: Writing – review & editing.

Conflict of interest
The authors declare no conflict of interest.

Approval of the research protocol by an Institutional Reviewer Board
Not applicable.

Informed consent
Informed consent was obtained from the patient for publication of the case details.

Registry and the Registration No. of the study/trial
Not applicable.

References
1 McCarty DJ, O’Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 1985; 254: 2763–7.
2 Olivieri I, Salvarani C, Cantini F. RS3PE syndrome: an overview. Clin. Exp. Rheumatol. 2000; 18(Suppl 20): 30–2.
3 Dolladille C, Ederhy S, Sassier M et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020; 6: 865–71.
4 Kostine M, Finckh A, Bingham CO et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann. Rheum. Dis. 2021; 80: 36–48.
5 Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 2014; 10: 662–70.
6 Cantini F, Salvarani C, Olivieri I. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clin. Exp. Rheumatol. 1999; 17: 741–4.
7 Yamamoto S, Fujita S, Mukai T, Sawachika H, Morita Y. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome should be treated with low-dose prednisolone during pembrolizumab therapy. Int. Med. 2020; 59: 597–8.
8 Arbour KC, Mezquita L, Long N et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer. J. Clin. Oncol. 2018; 36: 2872–8.
9 Weber JS, Hodi FS, Wolchok JD et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 2017; 35: 785–92.
10 Kim ST, Murphy WA, Aparicio A, Subudhi SK. Rs3pe following treatment with combination of hormonal therapies plus ipilimumab in a patient with metastatic prostate cancer. J. Immunother. Precis. Oncol. 2020; 3: 128–32.
11 Wada N, Uchi H, Furue M. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma. J. Dermatol. 2017; 44: e196–7.
12 Hansmaennel A, Verhoeven F, Chouk M, Prati C, Aubin F, Wendling D. RS1PE syndrome induced by Pembrolizumab. Jt. Bone Spine 2021; 88: 3–8.
13 Guacci M-L, Baroudjian B, Laly P et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. Semin. Arthritis Rheum. 2017; 47: 281–7.
14 Ngo L, Miller E, Valen P, Gertner E. Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report. J. Med. Case Rep. 2018; 12: 1–6.
15 Filetti M, Anselmi E, Macrini S et al. Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report. Semin. Arthritis Rheum. 2018; 48: e17–20.
16 Amini-Adle M, Piperno M, Tordo J et al. Remitting seronegative symmetric synovitis with pitting edema associated with partial melanoma response under anti-CTLA-4 and anti-programmed death 1 combination treatment. Arthritis Rheumatol. 2018; 70: 1358.
17 Redman JM, Rhea LP, Cordes L et al. A case of anti-PD-L1-associated remitting seronegative symmetric synovitis with pitting edema. Clin. Gastroenterol. Cancer 2019; 17: e549–52.